focus -WSS

focus

author：fashion 2025-10-01 18:44:25 - browse：14322

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

entertainment

WSS

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Delta passengers in Vegas fall sick while waiting on flight in triple

In rare move, senator releases unverified FBI source report alleging Biden bribe

The nurse manager staffing crisis is hurting patients

Hormonal contraceptives don’t actually treat endometriosis

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

explore

focus

focus

As demand for Covid shots wanes, Moderna seeks its next success

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Stanford president’s abrupt resignation sparks debate

Cancer drug shortages should be causing more outrage

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Medical leaders decry Supreme Court decision on affirmative action

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Hollywood unions extend contract negotiations for actors

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

explore

The SUPPORT Act is critical to fighting the opioid crisis

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Biotech reporter’s notebook: A sunnier mood at JPM 2024

New England Journal of Medicine addresses racist history, slavery

There’s a way to spot data fakery. All journals should be using it

hotspot

entertainment

entertainment

hotspot